Selection of chemotherapy for patients with advanced non-small cell lung cancer.

Abstract

Chemotherapy remains the first-line treatment for most patients with stage IV non-small cell lung cancer (NSCLC), but optimal regimens are now defined by histology. Platinum-based regimens with pemetrexed, bevacizumab, or both are reasonable first-line options for patients with nonsquamous NSCLC. The standard treatment for squamous NSCLC remains a platinum doublet with a drug other than pemetrexed. Maintenance therapy is emerging as a treatment strategy for patients who do not progress after four cycles of first-line chemotherapy. In the maintenance setting, pemetrexed and erlotinib significantly prolong overall survival compared with placebo after the completion of first-line chemotherapy.

• Authors: Nathan A Pennell
• Journal: Cleveland Clinic journal of medicine (Cleve Clin J Med) Vol. 79 Electronic Suppl 1 Pg. eS46-50 (May 2012) ISSN: 1939-2869 [Electronic] United States
• PMID: 22614966 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Protein Kinase Inhibitors
• Bevacizumab
• Cisplatin

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Bevacizumab
• Carcinoma, Non-Small-Cell Lung (drug therapy, mortality, pathology)
• Cisplatin (administration & dosage)
• Clinical Trials as Topic
• Humans
• Lung Neoplasms (drug therapy)
• Maintenance Chemotherapy (methods)
• Protein Kinase Inhibitors (administration & dosage)
• Survival Rate
• Treatment Outcome